I don't like the HC hype either but with all the things in the pipeline the $1.5m contrast is only just the beginning. The technology is there, the management is there, the contacts are there. It all just has to come together and contracts have to come to fruition. So there is definetely an element of risk. I understand AJX's model way better than most biotechs. Why for example PEB.NZX is trading so high I will not understand.